Last reviewed · How we verify
NCT04816500: RIC-SVD
Remote Ischemic Conditioning on Cerebral Small Vessel Disease
NA trial testing Automatic ischemic conditioning treatment instrument in Cerebral Small Vessel Diseases in 60 participants. Status unknown.
1 December 2021
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 January 2019 |
| Primary completion | 1 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Automatic ischemic conditioning treatment instrument
- Regular treatment — full drug profile →
Conditions studied
- Cerebral Small Vessel Diseases — all drugs for Cerebral Small Vessel Diseases →
Sponsor
Capital Medical University
Who can join
Adults 45 to 80, any sex, with Cerebral Small Vessel Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a randomized, controlled, single-center, double-blind trial. Cerebral small vessel disease (CSVD) patients will be recruited and randomized into RIC or control group.The protective effect of remote ischemic conditioning (RIC) on CSVD will be investigated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04816500
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebral Small Vessel Diseases
Currently open trials in the same condition.
- NCT07342075 — Registry Study of Cerebral Small Vessel Disease · recruiting
- NCT06579664 — Intermittent Theta Burst Stimulation on Cognitive Impairment of Cerebral Small Vessel Disease · NA · recruiting
- NCT06416371 — Retinal Vessel Leakage in Cerebral Small Vessel Disease · recruiting
- NCT06431711 — Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease · recruiting
- NCT06164262 — Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years · recruiting
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04816500 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 25 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04816500.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing